Competing interests
EAH
The study was funded by the Wellcome Trust (223016/Z/21/Z). JK is shareholder and director of P1vital Products Ltd which is the study sponsor and manufacturer of i-spero®. VR and LI are employed by P1vital Products Ltd. MBB is an adjunct member of the DMC. CS salary is partly funded by National Institute for Health Research (NIHR133788) and Medical Research Council (MR/S035753/1 and MR/X005070/1). TJ is supported by a grant from UK Medical Research Council (MC_UU_00002/14). EAH salary is part funded by Wellcome Trust (223016/Z/21/Z) via consultancy to P1vital Products Ltd. EAH is on the Board of Trustees of the MQ Foundation. EAH also receives funding from the Swedish Research Council, Rannís The Icelandic Research Fund, OAK foundation, The Lupina Foundation and AFA Försäkring. EAH developed the intervention approach and training in using it (Anenome™). EAH receives book royalties from Guildford Press and Oxford University Press, and receives occasional honoraria for conference keynotes and clinical workshops. All other authors declare no competing interests.